Robert Lande - Knight Therapeutics Independent Director
| GUD Stock | CAD 6.18 0.09 1.44% |
Director
Mr. Robert N. Lande is Independent Director of the Company. Mr. Lande is the President of FXCM Group LLC, a brokerage firm providing foreign exchange trading services through its electronic platform to clients globally. Formerly, he was Chief Financial Officer of Global Brokerage Inc., a shareholder in FXCM Group LLC. Previously, Mr. Lande was Managing Partner and Chief Operating Officer of Riveredge Capital Partners LLC and prior to that worked for over 16 years within the BCEBell Canada group where his last position was Chief Financial Officer of Telecom Amricas Ltd., a joint venture between Bell Canada International, ATT and America Movil. Mr. Lande is a Chartered Financial Analyst and holds an M.B.A. from the John Molson School of Business and a B.A. in Economics from McGill University. Mr. Lande was a director of Paladin from 1995 to 2014. since 2013.
| Age | 53 |
| Tenure | 12 years |
| Professional Marks | MBA |
| Address | 3400 de Maisonneuve Blvd. W., Montreal, QC, Canada, H3Z 3B8 |
| Phone | 514-484-4483 |
| Web | https://www.knighttx.com |
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Pierre Lortie | ECN Capital Corp | 72 | |
| Marc Poulin | Richelieu Hardware | 52 | |
| Andrea Rosen | Element Fleet Management | 64 | |
| Donald Chatterley | Winpak | N/A | |
| Mathieu Gauvin | Richelieu Hardware | N/A | |
| Rubin McDougal | Element Fleet Management | 62 | |
| Joan LammTennant | Element Fleet Management | 66 | |
| Karen Martin | ECN Capital Corp | 54 | |
| Rocco Colella | Element Fleet Management | N/A | |
| Dayna Spiring | Winpak | N/A | |
| Karen Albrechtsen | Winpak | N/A | |
| Paul Stoyan | ECN Capital Corp | 60 | |
| Martti AarnioWihuri | Winpak | N/A | |
| George Bunze | Stella Jones | 74 | |
| David Morris | ECN Capital Corp | 64 | |
| Robert Coallier | Stella Jones | 58 | |
| Karen Laflamme | Stella Jones | 56 | |
| Mary Webster | Stella Jones | 65 | |
| Alexander Greene | Element Fleet Management | 60 | |
| Robert Courteau | Richelieu Hardware | N/A | |
| Simon Pelletier | Stella Jones | 52 | |
Knight Therapeutics Leadership Team
Elected by the shareholders, the Knight Therapeutics' board of directors comprises two types of representatives: Knight Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Knight. The board's role is to monitor Knight Therapeutics' management team and ensure that shareholders' interests are well served. Knight Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Knight Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, Ex Chairman | ||
| Monica Percario, Global Affairs | ||
| Jonathan Goodman, Chief Executive Officer, Director | ||
| Robert Lande, Independent Director | ||
| Samira Sakhia, President, Chief Financial Officer, Director | ||
| BA LLB, Executive Chairman | ||
| Michael Tremblay, Independent Director | ||
| Susan Emblem, Global Resources | ||
| Nancy Harrison, Independent Director | ||
| Sylvie Tendler, Independent Director | ||
| Stephani Saverio, Vice Development | ||
| Meir Jakobsohn, Director | ||
| Henrique Dias, Global Marketing | ||
| Jeff Martens, Global Commercial | ||
| James Gale, Independent Chairman of the Board | ||
| Arvind Utchanah, Chief Financial Officer | ||
| Leopoldo Bosano, VicePresident Operations | ||
| Jody Engel, Senior Director - Business Development | ||
| Amal Khouri, Vice President - Business Development | ||
| Janice Murray, Independent Director | ||
| Nicolas Sujoy, Independent Director | ||
| Daniela Marino, Global Compliance | ||
| Melanie Groleau, Global Clinical |
Knight Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Knight Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Price To Earning | 133.90 X | ||||
| Revenue | 328.2 M | ||||
| EBITDA | 56.82 M | ||||
| Net Income | (16.84 M) | ||||
| Cash And Equivalents | 302 K | ||||
| Cash Per Share | 4.10 X | ||||
| Total Debt | 69.09 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 2.31 X | ||||
| Book Value Per Share | 7.53 X |
Pair Trading with Knight Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Knight Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Knight Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Knight Stock
Moving against Knight Stock
| 0.65 | BBD-B | Bombardier | PairCorr |
| 0.62 | ONEX | Onex Corp | PairCorr |
| 0.43 | MGA | Mega Uranium | PairCorr |
| 0.31 | CVE | Cenovus Energy | PairCorr |
The ability to find closely correlated positions to Knight Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Knight Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Knight Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Knight Therapeutics to buy it.
The correlation of Knight Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Knight Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Knight Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Knight Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.